- Hemogenyx Pharmaceuticals has chosen LakePharma as service provider for the development and manufacturing of Hemogenyx's lead product, CDX bi-specific antibodies.

The company believes that CDX bi-specific antibodies could replace traditional methods of conditioning patients for bone marrow transplants-eliminating the need for pre-transplantation chemotherapy and radiation, which can damage a patient's health-and allow more patients to benefit from the curative power of bone marrow transplants.

At 9:13am: [LON:HEMO] Hemogenyx Pharmaceuticals Plc Ord Gbp0.01 share price was 0p at 2.63p

Story provided by